Notícias e Atividades da Scandion Oncology

Scandion Oncology é uma empresa listada sob o símbolo SCOL (DK).

Veja o organograma con seus 9 executivos principais

Biografias mais buscadas da Scandion Oncology

• Francois Martelet, Chief Executive Officer
• Keld Flintholm Jørgensen, Board Member
• Alejandra Mørk, Vice Chairman of the Board

Criar um alerta
para seguir os movimentos de executivos da Scandion Oncology.

Scandion Oncology possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Scandion Oncology

• Scandion Oncology Announces Results of Annual General Meeting – Scandion Oncology
• Scandion Oncology – Notice convening the Annual General Meeting – Scandion Oncology
• Scandion Oncology – Annual Report 2024 – Scandion Oncology
• Scandion Oncology – Q4 & yearend report 2024 – Scandion Oncology
• Scandion Oncology’s Board of Directors emphasize need to find a partner before the Annual General Meeting – Scandion Oncology
• Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks – Scandion Oncology
• Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report – Scandion Oncology
• Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer – Scandion Oncology
• Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million – Scandion Oncology
• Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024 – Scandion Oncology
• View more press releases Close

Redes sociais sobre Scandion Oncology

• Scandion Oncology na Wikipedia, Google News e Yahoo Finance
• Scandion Oncology na LinkedIn, Twitter e YouTube